Cooperation Between Early Acting Delayed-Type Hypersensitivity T-cells and Cultured Effector Cells in Tumor Rejection

Cancer Research

Volumn 48, Issue 21, 1988, Pages 5922-5926

  Trial, Jo Ann ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; CELL CULTURE; DELAYED HYPERSENSITIVITY; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION;

ANIMAL; ANTIGENS, SURFACE; GRAFT REJECTION; HYPERSENSITIVITY, DELAYED; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES;

EID: 0023792381     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Van Loveren, H., and Askenase, P. W. Delayed-type hypersensitivity is mediated by a sequence of two different T cell activities. J. Immunol., 133: 2397-2401, 1984.
2. Van Loveren, H., Meade, R., and Askenase, P. W. An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J. Exp. Med., 757: 1604-1617, 1983.
3. Van Loveren, H., Den Otter, W., Meade, R., Terheggen, P. M. A. B., and Askenase, P. W. A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors. J. Immunol., 134: 1292-1299, 1985.
4. Flood, P. M., Schreiber, H., and Ron, Y. Protective immunity to progressive tumors can be induced by antigen presented on regresser tumors. J. Immunol., 138: 3573-3579, 1987.
5. Rosenstein, M., Eberlein, T. J., and Rosenberg, S. A. Adoptive immunotherapy of established syngeneic solid tumors: Role of T lymphoid subpopulations. J. Immunol., 132: 2117-2122, 1984.
6. Daily, M. O., Fathman, C. G., Butcher, E. C., Pillemer, E., and Weismann, I. Abnormal migration of T lymphocyte clones. J. Immunol., 128: 2134-2136, 1982.
7. Kripke, M. L. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst., 53: 1333-1336, 1974.
8. Kripke. M. L. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res., 37: 1395-1400, 1977.
9. Kripke, M. L., Thorn. R. M., Lili. P. H., Civin, C. I., Pazmino, N. H., and Fisher, M. S. Further characterization of immunological unresponsiveness induced in mice by ultraviolet radiation. Transplantation, 28: 212-217, 1979.
10. Dialynas, D. P., Wilde, D. B., Marrack, P., Pierres, A., Wall, K. A., Havran, W., Otten, G., Loken, M. R., Pierres, M., Kappler, J., and Fitch, F. W. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK 1.5: Expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigenreactivity. Immunol. Rev., 74: 29-56, 1983.
11. Ledbetter, J. A., and Herzenber, L. A. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol. Rev., 47: 63-90, 1979.
12. Gallatin, W. M., Weissman, I. L., and Butcher, E. C. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature (Lond.), 303: 30-34, 1983.
13. Wysocki, L. J., and Sato, V. L. “Panning” for lymphocytes: A method for cell selection. Proc. Natl. Acad. Sci. USA, 75: 2844-2848, 1978.
14. + T cell populations that mediate delayed-type hypersensitivity. J. Immunol., 133: 2402-2411, 1984.
15. Romerdahl, C. A., and Kripke, M. L. Regulation of the immune response against UV-induced skin cancers: Specificity of helper cells and their susceptibility to UV-induced suppressor cells. J. Immunol., 137: 3031-3035, 1986.
16. Bianchi, A. T. J., Hooijkass, H., Benner. R., Tees, R., Nordin, A. A., and Schreier, M. H. Clones of helper T cells mediate antigen-specific, H-2-restricted DTH. Nature (Lond.), 290: 62-63, 1981.
17. Smith, F., and Miller, J. F. Delayed type hypersensitivity to allogeneic cells in mice. I. Requirements for optimal sensitization and definition of the response. Int. Arch. Allergy Appi. Immunol., 58: 285-294, 1979.
18. Dennert, G., Weiss, S., and Warner, J. F. T cells may express multiple activities: Specific allohelp, cytolysis, and delayed-type hypersensitivity are expressed by a cloned T-cell line. Proc. Natl. Acad. Sci. USA, 78: 4540-4543, 1981.
19. Lili, P. H., and Fortner, G. W. Identification and cytotoxic reactivity of inflammatory cells recovered from progressing or regressing syngeneic UVinduced murine tumors. J. Immunol., 727: 1854-1860, 1978.
20. Donohue, J. H., Rosenstein. M., Chang, A. E., Lotze, M. T., Robb, R. J., and Rosenberg, S. A. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma J. Immunol., 132: 2123-2128, 1984.
21. Cheever, M. A., Thompson, D. B., Klarnet, J. P., and Greenberg, P. D. Antigen-driven long term-cultured T cell proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. Exp. Med., 163: 1100-1112, 1986.
22. Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. Extravasation of intravascular Muid mediated by systemic administration of recombinant 11, 2. J. Immunol., 137: 1735-1742, 1986.
23. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Lehman, S., Linchan. W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
24. West, W. H., Tauer, K. W., Yannelli, J. R., Marshall, G. D., Orr, D. W., Thurman, G. B., and Oldham, R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med., 316: 898-905, 1987.
25. Bucana, G., Trial, J., Papp, A. C., and Wu, K. K. Incubation of bovine aorta endothelial cells with IL-2 induces morphological changes that correlate with enhanced vascular permeability. Scanning Electron Microscopy, in press, 1988.